Emerging and critical issues in the pathogenesis of lupus

Autoimmunity Reviews

Volumn 12, Issue 4, 2013, Pages 523-536

  Gatto, Mariele ^a   Zen, Margherita ^a   Ghirardello, Anna ^a   Bettio, Silvano ^a   Bassi, Nicola ^a   Iaccarino, Luca ^a   Punzi, Leonardo ^a   Doria, Andrea ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Autoantibodies; Autoimmunity; Genetics; Lupus nephritis; Neuropsychiatric lupus; Pathogenesis; Systemic lupus erythematosus

Indexed keywords

ALPHA INTERFERON; AUTOANTIBODY; AUTOANTIGEN; B CELL ACTIVATING FACTOR; COMPLEMENT COMPONENT C3 RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; HLA DQA1 ANTIGEN; HLA DQB1 ANTIGEN; HLA DRB1 ANTIGEN; INTERFERON REGULATORY FACTOR; INTERFERON REGULATORY FACTOR 5; INTERFERON REGULATORY FACTOR 7; INTERLEUKIN 8; MICRORNA; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; PROTEIN KINASE ZAP 70; STAT4 PROTEIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9;

ADAPTIVE IMMUNITY; ANTIBODY PRODUCTION; ANTIGEN PRESENTING CELL; APOPTOSIS; B LYMPHOCYTE ACTIVATION; BASE PAIRING; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; CELL PROLIFERATION; CLONAL ANERGY; DENDRITIC CELL; DNA METHYLATION; GENE LINKAGE DISEQUILIBRIUM; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; GENOTYPE PHENOTYPE CORRELATION; HAPLOTYPE; HISTONE ACETYLATION; HISTONE MODIFICATION; HUMAN; IMMUNOSURVEILLANCE; INTRACELLULAR SIGNALING; LUPUS ERYTHEMATOSUS NEPHRITIS; MACROPHAGE ACTIVATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MONOCYTE; MYELOID DENDRITIC CELL; NEUTROPHIL; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE; X CHROMOSOME; ANIMAL; AUTOIMMUNITY; B LYMPHOCYTE; GENETIC EPIGENESIS; GENETICS; IMMUNOLOGY; METABOLISM; T LYMPHOCYTE;

ANIMALS; APOPTOSIS; AUTOANTIBODIES; AUTOIMMUNITY; B-LYMPHOCYTES; EPIGENESIS, GENETIC; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; T-LYMPHOCYTES;

MLCS; MLOWN;

EID: 84877821946     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.09.003     Document Type: Review

References (166)

1. Doria A., Iaccarino L., Ghirardello A., Zampieri S., Arienti S., Sarzi-Puttini P., et al. Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med 2006, 119:1497-1499.
2. Costenbader K.H., Gay S., Riquelme M.E., Iaccarino L., Doria A. Genes, epigenetic regulation and environmental factors: which is the most relevant in developing autoimmune diseases?. Autoimmun Rev 2012, 11:604-609.
3. Doria A., Zen M., Canova M., Bettio S., Bassi N., Nalotto L., et al. SLE diagnosis and treatment: when early is early. Autoimmun Rev 2010, 10:55-60.
4. Cervino A.C., Tsinoremas N.F., Hoffman R.W. A genome-wide study of lupus: preliminary analysis and data release. Ann N Y Acad Sci 2007, 1110:131-139.
5. Harley J.B., Alarcón-Riquelme M.E., Criswell L.A., Jacob C.O., Kimberly R.P., et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet 2008, 40:204-210. International Consortium for Systemic Lupus Erythematosus Genetics (SLEGEN).
6. Hom G., Graham R.R., Modrek B., Taylor K.E., Ortmann W., Garnier S., et al. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med 2008, 358:900-909.
7. Han J.W., Zheng H.F., Cui Y., Sun L.D., Ye D.Q., Hu Z., et al. Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet 2009, 41:1234-1237.
8. Kozyrev S.V., Abelson A.K., Wojcik J., Zaghlool A., Linga Reddy M.V., Sanchez E., et al. Functional variants in the B-cell gene BANK1 are associated with systemic lupus erythematosus. Nat Genet 2008, 40:211-216.
9. Yang W., Shen N., Ye D.Q., Liu Q., Zhang Y., Qian X.X., et al. Genome-wide association study in Asian populations identifies variants in ETS1 and WDFY4 associated with systemic lupus erythematosus. PLoS Genet 2010, 6:e1000841.
10. Cunninghame Graham D.S., Graham R.R., Manku H., Wong A.K., Whittaker J.C., Gaffney P.M., et al. Polymorphism at the TNF superfamily gene TNFSF4 confers susceptibility to systemic lupus erythematosus. Nat Genet 2008, 40:83-89.
11. Delgado-Vega A., Sánchez E., Löfgren S., Castillejo-López C., Alarcón-Riquelme M.E. Recent findings on genetics of systemic autoimmune diseases. Curr Opin Immunol 2010, 22:698-705.
12. Rhodes B., Vyse T.J. The genetics of SLE: an update in the light of genome-wide association studies. Rheumatology 2008, 47:1603-1611.
13. Fernando M.M., Freudenberg J., Lee A., Morris D.L., Boteva L., Rhodes B., et al. Transancestral mapping of the MHC region in systemic lupus erythematosus identifies new independent and interacting loci at MSH5, HLA-DPB1 and HLA-G. Ann Rheum Dis 2012, 71:777-784.
14. Taylor K.E., Chung S.A., Graham R.R., Ortmann W.A., Lee A.T., Langefeld C.D., et al. Risk alleles for systemic lupus erythematosus in a large case-control collection and associations with clinical subphenotypes. PLoS Genet 2011, 7:e1001311.
15. Fu S.M., Deshmukh U.S., Gaskin F. Pathogenesis of systemic lupus erythematosus revisited 2011: end organ resistance to damage, autoantibody initiation and diversification, and HLA-DR. J Autoimmun 2011, 37:104-112.
16. Rönnblom L. The type I interferon system in the etiopathogenesis of autoimmune diseases. Ups J Med Sci 2011, 116:227-237.
17. Niewold T.B., Clark D.N., Salloum R., Poole B.D. Interferon alpha in systemic lupus erythematosus. J Biomed Biotechnol 2010, 2010:948364.
18. Sigurdsson S., Göring H.H., Kristjansdottir G., Milani L., Nordmark G., Sandling J.K., et al. Comprehensive evaluation of the genetic variants of interferon regulatory factor 5 reveals a novel 5bp length polymorphism as strong risk factor for systemic lupus erythematosus. Hum Mol Genet 2008, 17:872-881.
19. Graham R.R., Kyogoku C., Sigurdsson S., Vlasova I.A., Davies L.R., Baechler E.C., et al. Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc Natl Acad Sci U S A 2007, 104:6758-6763.
20. Niewold T.B., Kelly J.A., Flesch M.H., Espinoza L.R., Harley J.B., Crow M.K. Association of the IRF5 risk haplotype with high serum interferon-a activity in systemic lupus erythematosus patients. Arthritis Rheum 2008, 58:2481-2487.
21. Remmers E.F., Plenge R.M., Lee A.T., Graham R.R., Hom G., Behrens T.W., et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 2007, 357:977-986.
22. Abelson A.K., Delgado-Vega A.M., Kozyrev S.V., Sánchez E., Velázquez-Cruz R., Eriksson N., et al. STAT4 associates with systemic lupus erythematosus through two independent effects that correlate with gene expression and act additively with IRF5 to increase risk. Ann Rheum Dis 2009, 68:1746-1753.
23. Graham R.R., Cotsapas C., Davies L., Hackett R., Lessard C.J., Leon J.M., et al. Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. Nat Genet 2008, 40:1059-1061.
24. Lee Y.H., Lee H.S., Choi S.J., Ji J.D., Song G.G. Associations between the polymorphisms of TLR and systemic lupus erythematosus: a systematic review and meta-analysis. Clin Exp Rheumatol 2012, 30:262-265.
25. Oropallo M.A., Kiefer K., Marshak-Rothstein A., Cancro M.P. Beyond transitional selection: new roles for BLyS in peripheral tolerance. Drug Dev Res 2011, 72:779-787.
26. Hackl D., Loschko J., Sparwasser T., Reindl W., Krug A.B. Activation of dendritic cells via TLR7 reduces Foxp3 expression and suppressive function in induced Tregs. Eur J Immunol 2011, 41:1334-1343.
27. Celhar T., Magalhães R., Fairhurst A.M. TLR7 and TLR9 in SLE: when sensing self goes wrong. Immunol Res 2012, 53:58-77.
28. Kwok Sk, Lee J.Y., Park S.H., Cho M.L., Min S.Y., Park S.H., et al. Dysfunctional interferon-alpha production by peripheral plasmacytoid dendritic cells upon Toll-like receptor-9 stimulation in patients with systemic lupus erythematosus. Arthritis Res Ther 2008, 10:R29.
29. Merril J.T., Wallace D.J., Petri M., Kirou K.A., Yao Y., White W.I., et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis 2011, 70:1905-1913.
30. Chung S.A., Criswell L.A. PTPN22: its role in SLE and autoimmunity. Autoimmunity 2007, 40:582-590.
31. Niederer H.A., Clatworthy M.R., Willcocks L.C., Smith K.G. FcgammaRIIB, FcgammaRIIIB, and systemic lupus erythematosus. Ann N Y Acad Sci 2010, 1183:69-88.
32. Fanciulli M., Norsworthy P.J., Petretto E., Dong R., Harper L., Kamesh L., et al. FCGR3B copy number variation is associated with susceptibility to systemic, but not organ specific, autoimmunity. Nat Genet 2007, 39:721-723.
33. Paul E., Nelde A., Verschoor A., Carroll M.C. Follicular exclusion of autoreactive B cells requires FcgammaRIIb. Int Immunol 2007, 19:365-373.
34. Xiang Z., Cutler A.J., Brownlie R.J., Fairfax K., Lawlor K.E., Severinson E., et al. FcgammaRIIb controls bone marrow plasma cell persistence and apoptosis. Nat Immunol 2007, 8:419-429.
35. Floto R.A., Clatworthy M.R., Heilbronn K.R., Rosner D.R., MacAry P.A., Rankin A., et al. Loss of function of a lupus associated FcgammaRIIb polymorphism through exclusion from lipid rafts. Nat Med 2005, 11:1056-1058.
36. Webb R., Wren J.D., Jeffries M., Kelly J.A., Kaufman K.M., Tang Y., et al. Variants within MECP2, a key transcription regulator, are associated with increased susceptibility to lupus and differential gene expression in patients with systemic lupus erythematosus. Arthritis Rheum 2009, 60:1076-1084.
37. Lu Q., Wu A., Tesmer L., Ray D., Yousif N., Richardson B. Demethylation of CD40LG on the inactive Z in T cells from women with lupus. J Immunol 2007, 179:6352-6358.
38. Sanchez E., Nadig A., Richardson B.C., Freedman B.I., Kaufman K.M., Kelly J.A., et al. Phenotypic associations of genetic susceptibility loci in systemic lupus erythematosus. Ann Rheum Dis 2011, 70:1752-1757.
39. Salmon J.E., Millard S., Schachter L.A., Arnett F.C., Ginzler E.M., Gourley M.F., et al. Fc gamma RIIA alleles are heritable risk factors for lupus nephritis in African Americans. J Clin Invest 1996, 97:1348-1354.
40. Patschan S., Dolff S., Kribben A., Dürig J., Patschan D., Wilde B., et al. CD134 expression on CD4+ T cells is associated with nephritis and disease activity in patients with systemic lupus erythematosus. Clin Exp Immunol 2006, 145:235-242.
41. Odobasic D., Kitching A.R., Tipping P.G., Holdsworth S.R. CD80 and CD86 costimulatory molecules regulate crescentic glomerulonephritis by different mechanisms. Kidney Int 2005, 68:584-594.
42. Renaudineau Y., Youinou P. Epigenetics and autoimmunity, with special emphasis on methylation. Keio J Med 2011, 60:10-16.
43. Hedrich C.M., Tsokos G.C. Epigenetic mechanisms in systemic lupus erythematosus and other autoimmune diseases. Trends Mol Med 2011, 17:714-724.
44. Zouali M. Epigenetics in lupus. Ann N Y Acad Sci 2011, 1217:154-156.
45. Gorelik G., Fang J.Y., Wu A., Sawalha A.H., Richardson B. Impaired T cell protein kinase C delta activation decreases ERK pathway signaling in idiopathic and hydralazine-induced lupus. J Immunol 2007, 179:5553-5563.
46. Koutouzov S., Jeronimo A.L., Campos H., Amoura Z. Nucleosomes in the pathogenesis of systemic lupus erythematosus. Rheum Dis Clin North Am 2004, 30:529-558.
47. Ballestar E. Epigenetic alterations in autoimmune rheumatic diseases. Nat Rev Rheumatol 2011, 7:263-271.
48. Vaissière T., Sawan C., Herceg Z. Epigenetic interplay between histone modifications and DNA methylation in gene silencing. Mutat Res 2008, 659:40-48.
49. Reilly C.M., Regna N., Mishra N. HDAC inhibition in lupus models. Mol Med 2011, 17:417-425.
50. Nambiar M.P., Warke V.G., Fisher C.U., Tsokos G.C. Effect of trichostatin A on human T cells resembles signaling abnormalities in T cells of patients with systemic lupus erythematosus: a new mechanism for TCR zeta chain deficiency and abnormal signaling. J Cell Biochem 2002, 85:459-469.
51. Amarilyo G., La Cava A. miRNA in systemic lupus erythematosus. Clin Immunol 2012, 144:26-31.
52. Yurasov S., Wardemann H., Hammersen J., Tsuiji M., Meffre E., Pascual V., et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med 2005, 201:703-711.
53. Mandik-Nayak L., Ridge N., Fields M., Park A.Y., Erikson J. Role of B cells in systemic lupus erythematosus and rheumatoid arthritis. Curr Opin Immunol 2008, 20:639-645.
54. Moulton V.R., Tsokos G.C. Abnormalities of T cell signaling in systemic lupus erythematosus. Arthritis Res Ther 2011, 13:207.
55. Crispin J.C., Kyttaris V.C., Juang Y.T., Tsokos G.C. How signaling and gene transcription aberrations dictate the systemic lupus erythematosus T cell phenotype. Trends Immunol 2008, 29:110-115.
56. Peng S.L. Altered T, and B lymphocyte signaling pathways in lupus. Autoimmun Rev 2009, 8:179-183.
57. Kyttaris V.C., Zhang Z., Kampagianni O., Tsokos G.C. Calcium signaling in systemic lupus erythematosus T cells: a treatment target. Arthritis Rheum 2011, 63:2058-2066.
58. Krishnan S., Chowdhury B., Tsokos G.C. Autoimmunity in systemic lupus erythematosus: integrating genes and biology. Semin Immunol 2006, 18:230-243.
59. Crispin J.C., Tsokos G.C. Human TCR-alpha beta+ CD4- CD8- T cells can derive from CD8+ T cells and display an inflammatory effector phenotype. J Immunol 2009, 183:4675-4681.
60. Jenks S.A., Sanz I. Altered B cell receptor signaling in human systemic lupus erythematosus. Autoimmun Rev 2009, 8:209-213.
61. Flores-Borja F., Kabouridis P.S., Jury E.C., Isenberg D.A., Mageed R.A. Decreased Lyn expression and translocation to lipid raft signaling domains in B lymphocytes from patients with systemic lupus erythematosus. Arthritis Rheum 2005, 52:3955-3965.
62. Flores-Borja F., Kabouridis P.S., Jury E.C., Isenberg D.A., Mageed R.A. Altered lipid raft-associated proximal signaling and translocation of CD45 tyrosine phosphatase in B lymphocytes from patients with systemic lupus erythematosus. Arthritis Rheum 2007, 56:291-302.
63. Shahaf G., Gross A.J., Sternberg-Simon M., Kaplan D., DeFranco A.L., Mehr R. Lyn deficiency affects B-cell maturation as well as survival. Eur J Immunol 2012, 42:511-521.
64. Rhee I., Veillette A. Protein tyrosine phosphatases in lymphocyte activation and autoimmunity. Nat Immunol 2012, 13:439-447.
65. Dörner T., Giesecke C., Lipsky P.E. Mechanisms of B cell autoimmunity in SLE. Arthritis Res Ther 2011, 13:243.
66. Booth J., Wilson H., Jimbo S., Mutwiri G. Modulation of B cell responses by Toll-like receptors. Cell Tissue Res 2011, 343:131-140.
67. Rawlings D.J., Schwartz M.A., Jackson S.W., Meyer-Bahlburg A. Integration of B cell responses through Toll-like receptors and antigen receptors. Nat Rev Immunol 2012, 12:282-294.
68. Pone E.J., Zhang J., Mai T., White C.A., Li G., Sakakura J.K., et al. BCR-signaling synergizes with TLR-signaling for induction of AID and immunoglobulin class-switching through the non-canonical NF-κB pathway. Nat Commun 2012, 3:767.
69. Muñoz L.E., Lauber K., Schiller M., Manfredi A.A., Herrmann M. The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat Rev Rheumatol 2010, 6:280-289.
70. Mayer B., Oberbauer R. Mitochondrial regulation of apoptosis. News Physiol Sci 2003, 18:89-94.
71. Shoshan Y., Shapira I., Toubi E., Frolkis I., Yaron M., Mevorach D. Accelerated Fas-mediated apoptosis of monocytes and maturing macrophages from patients with systemic lupus erythematosus: relevance to in vitro impairment of interaction with iC3b-opsonized apoptotic cells. J Immunol 2001, 167:5963-5969.
72. Courtney P.A., Crockard A.D., Williamson K., Irvine A.E., Kennedy R.J., Bell A.L. Increased apoptotic peripheral blood neutrophils in systemic lupus erythematosus: relations with disease activity, antibodies to double stranded DNA, and neutropenia. Ann Rheum Dis 1999, 58:309-314.
73. Whang H., Xu J., Ji X., Yang X., Sun K., Liu X., et al. The abnormal apoptosis of T cell subsets and possible involvement of IL-10 in systemic lupus erythematosus. Cell Immunol 2005, 235:117-121.
74. Xue C., Lan-Lan W., Bei C., Jie C., Wei-Hua F. Abnormal Fas/FasL and caspase-3-mediated apoptotic signaling pathways of T lymphocyte subset in patients with systemic lupus erythematosus. Cell Immunol 2006, 239:121-128.
75. Jin O., Sun L.Y., Zhou K.X., Zhang X.S., Feng X.B., Mok M.Y., et al. Lymphocyte apoptosis and macrophage function: correlation with disease activity in systemic lupus erythematosus. Clin Rheumatol 2005, 24:107-110.
76. Chen V.S., Nie Y.J., Shen N., Yan S., Mok M.Y., Lau C.S. Distinct roles of myeloid and plasmacytoid dendritic cells in systemic lupus erythematosus. Autoimmun Rev Mar 20 2012, (Epub ahead of print).
77. Manea M.E., Mueller R.B., Dejica D., Sheriff A., Schett G., Herrmann M., et al. Increased expression of CD154 and FAS in SLE patients' lymphocytes. Rheumatol Int 2009, 30:181-185.
78. Rastin M., Hatef M.R., Tabasi N., Mahmoudi M. The pathway of estradiol-induced apoptosis in patients with systemic lupus erythematosus. Clin Rheumatol 2012, 31:417-424.
79. Radic M., Herrmann M., van der Vlag J., Rekvig O.P. Regulatory and pathogenetic mechanisms of autoantibodies in SLE. Autoimmunity 2011, 44:349-356.
80. Kruse C., Janko C., Urbonaviciute V., Mierke C.T., Winkler T.H., Voll R.E., et al. Inefficient clearance of dying cells in patients with SLE: anti-dsDNA autoantibodies, MFG-E8, HMGB-1 and other players. Apoptosis 2010, 15:1098-1113.
81. Harris H.E., Andersson U., Pisetsky D.S. HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol 2012, 8:195-202.
82. Fransen J.H., van der Vlag J., Ruben J., Adema G.J., Berden J.H., Hilbrands L.B. The role of dendritic cells in the pathogenesis of systemic lupus erythematosus. Arthritis Res Ther 2010, 12:207.
83. Sfriso P., Ghirardello A., Botsios C., Tonon M., Zen M., Bassi N., et al. Infections and autoimmunity: the multifaceted relationship. J Leukoc Biol 2010, 87:385-395.
84. Pisetsky D.S., Gauley J., Ullal A.J. Microparticles as a source of extracellular DNA. Immunol Res 2011, 49:227-234.
85. Pisetsky D.S., Lipsky P.E. Microparticles as autoadjuvants in the pathogenesis of SLE. Nat Rev Rheumatol 2010, 6:368-372.
86. Munoz L.E., Janko C., Chaurio R.A., Schett G., Gaipl U.S., Herrmann M. IgG opsonized nuclear remnants from dead cells cause systemic inflammation in SLE. Autoimmunity 2010, 43:232-235.
87. Papayannopoulos V., Zychlinsky A. NETs: a new strategy for using old weapons. Trends Immunol 2009, 30:513-521.
88. Villanueva E., Yalavarthi S., Berthier C.C., Hodgin J.B., Khandpur R., Lin A.M., et al. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol 2011, 187:538-552.
89. Bosch X. Systemic lupus erythematosus and the neutrophil. N Engl J Med 2011, 365:758-760.
90. Fuchs T.A., Abed U., Goosmann C., Hurwitz R., Schulze I., Wahn V., et al. Novel cell death program leads to neutrophil extracellular traps. J Cell Biol 2007, 176:231-241.
91. Leffler J., Martin M., Gullstrand B., Tydén H., Lood C., Truedsson L., et al. Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease. J Immunol 2012, 188:3522-3531.
92. Yu S.L., Kuan W.P., Wong C.K., Li E.K., Tam L.S. Immunopathological roles of cytokines, chemokines, signaling molecules, and pattern-recognition receptors in systemic lupus erythematosus. Clin Dev Immunol 2012, 2012:715190.
93. Denny M.F., Yalavarthi S., Zhao W., Thacker S.G., Anderson M., Sandy A.R., et al. A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs. J Immunol 2010, 184:3284-3297.
94. Torres-Aguilar H., Blank M., Jara L.J., Shoenfeld Y. Tolerogenic dendritic cells in autoimmune diseases: crucial players in induction and prevention of autoimmunity. Autoimmun Rev 2010, 10:8-17.
95. Hakkim A., Fürnrohr B.G., Amann K., Laube B., Abed U.A., Brinkmann V., et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci U S A 2010, 107:9813-9818.
96. Jin O., Kavikondala S., Mok M.Y., Sun L., Gu J., Fu R., et al. Abnormalities in circulating plasmacytoid dendritic cells in patients with systemic lupus erythematosus. Arthritis Res Ther 2010, 12:R137.
97. Sherer Y., Gorstein A., Fritzler M.J., Shoenfeld Y. Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum 2004, 34:501-537.
98. Ching K.H., Burbelo P.D., Tipton C., Wei C., Petri M., Sanz I., et al. Two major autoantibody clusters in systemic lupus erythematosus. PLoS One 2012, 7:e32001.
99. Meffre E., Wardemann H. B-cell tolerance checkpoints in health and autoimmunity. Curr Opin Immunol 2008, 20:632-638.
100. Basten A., Silveira P.A. B-cell tolerance: mechanisms and implications. Curr Opin Immunol 2010, 22:566-574.
101. Cancro M., D'Cruz D.P., Khamashta M.A. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest 2009, 119:1066-1073.
102. Doria A., Sarzi-Puttini P., Shoenfeld Y. Infections rheumatism and autoimmunity. the conflicting relationship between humans and their environment. Autoimmun Rev 2008, 8:1-4.
103. Doria A., Canova M., Tonon M., Zen M., Rampudda E., Bassi N., et al. Infections as triggers and complications of systemic lupus erythematosus. Autoimmun Rev 2008, 8:24-28.
104. Zandman-Goddard G., Solomon M., Rosman Z., Peeva E., Shoenfeld Y. Environment and lupus-related diseases. Lupus 2012, 21:241-250.
105. Sarzi-Puttini P., Atzeni F., Iaccarino L., Doria A. Environment and systemic lupus erythematosus: an overview. Autoimmunity 2005, 38:465-472.
106. Meyers G., Ng Y.S., Bannock J.M., Lavoie A., Walter J.E., Notarangelo L.D., et al. Activation-induced cytidine deaminase (AID) is required for B-cell tolerance in humans. Proc Natl Acad Sci U S A 2011, 108:11554-11559.
107. Liu S., Velez M.G., Humann J., Rowland S., Conrad F.J., Halverson R., et al. Receptor editing can lead to allelic inclusion and development of B cells that retain antibodies reacting with high avidity autoantigens. J Immunol 2005, 175:5067-5076.
108. Mckay F., Schneider P. Cracking the BAFF code. Nat Rev Immunol 2009, 9:491-502.
109. Landolt-Marticorena C., Wither R., Reich H., Herzenberg A., Scholey J., Gladman D.D., et al. Increased expression of B cell activation factor supports the abnormal expansion of transitional B cells in systemic lupus erythematosus. J Rheumatol 2011, 38:642-651.
110. Petri M., Stohl W., Chatham W., McCune W.J., Chevrier M., Ryel J., et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2008, 58:2453-2459.
111. Furie R., Petri M., Zamani O., Cervera R., Wallace D.J., Tegzová D., et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011, 63:3918-3930.
112. Navarra S.V., Guzmán R.M., Gallacher A.E., Hall S., Levy R.A., Jimenez R.E., et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011, 377:721-731.
113. Lemoine S., Morva A., Youinou P., Jamin C. Human T cells induce their own regulation through activation of B cells. J Autoimmun 2011, 36:228-238.
114. Mauri C., Blair P.A. Regulatory B cells in autoimmunity: developments and controversies. Nat Rev Rheumatol 2010, 6:636-643.
115. Bouaziz J.D., Yanaba K., Tedder T.F. Regulatory B cells as inhibitors of immune responses and inflammation. Immunol Rev 2008, 224:201-214.
116. DiLillo D.J., Matsushita T., Tedder T.F. B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Ann N Y Acad Sci 2010, 1183:38-57.
117. Blair P.A., Noreña L.Y., Flores-Borja F., Rawlings D.J., Isenberg D.A., Ehrenstein M.R., et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity 2010, 32:129-140.
118. Kessel A., Haj T., Peri R., Snir A., Melamed D., Sabo E., et al. Human CD19(+)CD25(high) B regulatory cells suppress proliferation of CD4(+) T cells and enhance Foxp3 and CTLA-4 expression in T-regulatory cells. Autoimmun Rev 2012, 11:670-677.
119. Lund F.E., Randall T.D. Effector and regulatory B cells: modulators of CD4(+) T cell immunity. Nat Rev Immunol 2010, 10:236-247.
120. Duddy M.E., Alter A., Bar-Or A. Distinct profiles of human B cell effector cytokines: a role in immune regulation?. J Immunol 2004, 172:3422-3427.
121. Duan B., Croker B.P., Morel L. Lupus resistance is associated with marginal zone abnormalities an NZM murine model. Lab Invest 2007, 87:14-28.
122. Sharma A., Isenberg D.A., Diamond B. Crossreactivity of human anti-dsDNA antibodies to phosphorylcholine: clues to their origin. J Autoimmun 2001, 16:479-484.
123. Radbruch A., Muehlinghaus G., Luger E.O., Inamine A., Smith K.G., Dörner T., et al. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol 2006, 6:741-750.
124. Hiepe F., Dörner T., Hauser A.E., Hoyer B.F., Mei H., Radbruch A. Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat Rev Rheumatol 2011, 7:170-178.
125. Starke C., Frey S., Wellmann U., Urbonaviciute V., Herrmann M., Amann K., et al. High frequency of autoantibody-secreting cells and long-lived plasma cells within inflamed kidneys of NZB/W F1 lupus mice. Eur J Immunol 2011, 41:2107-2112.
126. Rekvig O.P., Putterman C., Casu C., Gao H.X., Ghirardello A., Mortensen E.S., et al. Autoantibodies in lupus: culprits or passive bystanders?. Autoimmun Rev 2012, 11:596-603.
127. Gutiérrez-Adrianzén O.A., Koutouzov S., Mota R.M., das Chagas Medeiros M.M., Bach J.F., de Holanda Campos H. Diagnostic value of anti-nucleosome antibodies in the assessment of disease activity of systemic lupus erythematosus: a prospective study comparing anti-nucleosome with anti-dsDNA antibodies. J Rheumatol 2006, 33:1538-1544.
128. Ghirardello A., Villalta D., Morozzi G., Afeltra A., Galeazzi M., Gerli R., et al. Diagnostic accuracy of currently available anti-double-stranded DNA antibody assays. An Italian multicentre study. Clin Exp Rheumatol 2011, 29:50-56.
129. Doria A., Briani C. Primary prevention of systemic lupus erythematosus. Nat Clin Pract Rheumatol 2008, 4:576-577.
130. Bizzaro N., Villalta D., Giavarina D., Tozzoli R. Are anti-nucleosome antibodies a better diagnostic marker than anti-dsDNA antibodies for systemic lupus erythematosus? A systematic review and a study of metanalysis. Autoimmun Rev Jul 15 2012, (Epub ahead of print).
131. Ghirardello A., Doria A., Zampieri S., Tarricone E., Tozzoli R., Villalta D., et al. Antinucleosome antibodies in SLE: a two-year follow-up study of 101 patients. J Autoimmun. 2004, 22:235-240.
132. Pisetsky D.S. Antinuclear antibodies in rheumatic disease: a proposal for a function-based classification. Scand J Immunol Jun 5 2012, (Epub ahead of print).
133. Pickering M.C., Botto M. Are anti-C1q antibodies different from other SLE autoantibodies?. Nat Rev Rheumatol 2010, 6:490-493.
134. Sinico R.A., Rimoldi L., Radice A., Bianchi L., Gallelli B., Moroni G. Anti-C1q autoantibodies in lupus nephritis. Ann N Y Acad Sci 2009, 1173:47-51.
135. Braun A., Sis J., Max R., Mueller K., Fiehn C., Zeier M., et al. Anti-chromatin and anti-C1q antibodies in systemic lupus erythematosus compared to other systemic autoimmune diseases. Scand J Rheumatol 2007, 36:291-298.
136. Karassa F.B., Afeltra A., Ambrozic A., Chang D.-M., De Keyser F., Doria A., et al. Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum 2006, 54:312-324.
137. Hanly J.G., Urowitz M.B., Su L., Bae S.C., Gordon C., Clarke A., et al. Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus. Ann Rheum Dis 2011, 70:1726-1732.
138. Briani C., Lucchetta M., Ghirardello A., Toffanin E., Zampieri S., Ruggero S., et al. Neurolupus is associated with anti-ribosomal P protein antibodies: an inception cohort study. J Autoimmun 2009, 32:79-84.
139. Ghirardello A., Briani C., Lucchetta M., Doria A. Anti-ribosomal P protein antibodies and neuropsychiatric systemic lupus erythematosus: cross-sectional vs. prospective studies. Lupus 2010, 19:771-773.
140. Ghirardello A., Caponi L., Franceschini F., Zampieri S., Gambari P.F., Doria A. Diagnostic tests for antiribosomal P protein antibodies: a comparative evaluation of immunoblotting and ELISA assays. J Autoimmun. 2002, 19:71-77.
141. Ghirardello A., Doria A., Zampieri S., Gerli R., Rapizzi E., Gambari P.F. Anti ribosomal P protein antibodies detected by immunoblotting in patients with connective tissue diseases: their specificity for SLE and association with the IgG anticardiolipin antibodies. Ann Rheum Dis 2000, 59:975-981.
142. Lauvsnes M.B., Omdal R. Systemic lupus erythematosus, the brain, and anti-NR2 antibodies. J Neurol 2012, 259:622-629.
143. Zandman-Goddard G., Chapman J., Shoenfeld Y. Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome. Semin Arthritis Rheum 2007, 36:297-315.
144. Faust T.W., Chang E.H., Kowal C., Berlin R., Gazaryan I.G., Bertini E., et al. Neurotoxic lupus autoantibodies alter brain function through two distinct mechanisms. Proc Natl Acad Sci U S A 2010, 107:18569-18574.
145. Diamond B. Losing your nerves? Maybe it's the antibodies. Nat Rev Immunol 2009, 9:449-456.
146. Katzav A., Solodeev I., Brodsky O., Chapman J., Pick C.G., Blank M., et al. Induction of autoimmune depression in mice by anti-ribosomal P antibodies via the limbic system. Arthritis Rheum 2007, 56:938-948.
147. Zampieri S., Mahler M., Blüthner M., Qiu Z., Malmegrim K., Ghirardello A., et al. Recombinant anti-P proteins autoantibodies isolated from a human autoimmune library: reactivity, specificity and epitope recognition. Cell Mol Life Sci 2003, 60:588-598.
148. Matus S., Burgos P.V., Bravo-Zehnder M., Kraft R., Porras O.H., Farías P., et al. Antiribosomal-P autoantibodies from psychiatric lupus target a novel neuronal surface protein causing calcium influx and apoptosis. J Exp Med 2007, 204:3221-3234.
149. Zampieri S., Degen W., Ghirardello A., Doria A., van Venrooij W.J. Dephosphorylation of autoantigenic ribosomal P proteins during FAS-L induced apoptosis; a possible trigger for the development of the autoimmune response in SLE patients. Ann Rheum Dis 2001, 60:72-76.
150. Strous R.D., Shoenfeld Y. To smell the immune system: olfaction, autoimmunity and brain involvement. Autoimmun Rev 2006, 6:54-60.
151. Shoenfeld N., Agmon-Levin N., Flitman-Katzevman I., Paran D., Katz B.S., Kivity S., et al. The sense of smell in systemic lupus erythematosus. Arthritis Rheum 2009, 60:1484-1487.
152. Arinuma Y., Yanagida T., Hirohata S. Association of cerebrospinal fluid anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 2008, 58:1130-1135.
153. Levin E.C., Acharya N.K., Han M., Zavareh S.B., Sedeyn J.C., Venkataraman V., et al. Brain-reactive autoantibodies are nearly ubiquitous in human sera and may be linked to pathology in the context of blood-brain barrier breakdown. Brain Res 2010, 1345:221-232.
154. van Bavel C.C., Fenton K.A., Rekvig O.P., van der Vlag J., Berden J.H. Glomerular targets of nephritogenic autoantibodies in systemic lupus erythematosus. Arthritis Rheum 2008, 58:1892-1899.
155. Kaalaji M., Fenton K.A., Mortensen E.S., Olsen R., Sturfelt G., Alm P., et al. Glomerular apoptotic nucleosomes are central target structures for nephritogenic antibodies in human SLE nephritis. Kidney Int 2007, 71:664-672.
156. Faurschou M., Penkowa M., Andersen C.B., Starklint H., Jacobsen S. Renal cell apoptosis in human lupus nephritis: a histological study. Lupus 2009, 18:994-999.
157. Mjelle J.E., Kalaaji M., Rekvig O.P. Exposure of chromatin and not high affinity for dsDNA determines the nephritogenic impact of anti-dsDNA antibodies in (NZBxNZW)F1 mice. Autoimmunity 2009, 42:104-111.
158. Shoenfeld Y., Szyper-Kravitz M., Witte T., Doria A., Tsutsumi A., Tatsuya A., et al. Autoantibodies against protective molecules-C1q, C-reactive protein, serum amyloid P, mannose-binding lectin, and apolipoprotein A1: prevalence in systemic lupus erythematosus. Ann N Y Acad Sci 2007, 1108:227-239.
159. Figueredo M.A., Rodriguez A., Ruiz-Yagüe M., Romero M., Fernandez-Cruz A., Gomez-de la Concha E., et al. Autoantibodies against C-reactive protein: clinical associations in systemic lupus erythematosus and primary antiphospholipid syndrome. J Rheumatol 2006, 33:1980-1986.
160. Manfredi A.A., Rovere-Querini P., Bottazzi B., Garlanda C., Mantovani A. Pentraxins, humoral innate immunity and tissue injury. Curr Opin Immunol 2008, 20:538-544.
161. Jaillon S., Peri G., Delneste Y., Frémaux I., Doni A., Moalli F., et al. The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps. J Exp Med 2007, 204:793-804.
162. Nauta A.J., de Haij S., Bottazzi B., Mantovani A., Borrias M.C., Aten J., et al. Human renal epithelial cells produce the long pentraxin PTX3. Kidney Int 2005, 67:543-553.
163. Nauta A.J., Bottazzi B., Mantovani A., Salvatori G., Kishore U., Schwaeble W.J. Biochemical and functional characterization of the interaction between pentraxin 3 and C1q. Eur J Immunol 2003, 33:465-473.
164. Rovere P., Peri G., Fazzini F., Bottazzi B., Doni A., Bondanza A., et al. The long pentraxin PTX3 binds to apoptotic cells and regulates their clearance by antigen-presenting dendritic cells. Blood 2000, 96:4300-4306.
165. Bassi N., Ghirardello A., Blank M., Zampieri S., Sarzi-Puttini P., Mantovani A., et al. IgG anti-pentraxin 3 antibodies in systemic lupus erythematosus. Ann Rheum Dis 2010, 69:1704-1710.
166. Doria A, Gatto M. Nephritogenic-antinephritogenic antibody network in lupus glomerulonephritis. Lupus in press.